Join
Live feed
·
PRReleasevia Quantisnow
Relmada Therapeutics Inc. logo

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
RLMD· Relmada Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLMD (Relmada Therapeutics Inc.) and more on Quantisnow.